Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 362
- Registration Number
- NCT00604253
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety of Insulin Detemir in Children With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 83
- Registration Number
- NCT00605137
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 477
- Registration Number
- NCT00604396
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Umeå, Sweden
Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT00604344
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer
Phase 2
Terminated
- Conditions
- CancerMalignant Melanoma
- Interventions
- Drug: recombinant interleukin-21
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1
- Registration Number
- NCT00601861
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 394
- Registration Number
- NCT00600626
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00600366
- Locations
Novo Nordisk Investigational Site, Novi Sad, Former Serbia and Montenegro
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 242
- Registration Number
- NCT00598793
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Renton, Washington, United States
Human Insulin NPH and Insulin Aspart in Type 1 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 91
- Registration Number
- NCT00597233
- Locations
- 🇦🇷
Novo Nordisk Investigational Site, Junin, Argentina
Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 114
- Registration Number
- NCT00595374
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Zwolle, Netherlands
© Copyright 2025. All Rights Reserved by MedPath